JP2006525226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525226A5 JP2006525226A5 JP2005509680A JP2005509680A JP2006525226A5 JP 2006525226 A5 JP2006525226 A5 JP 2006525226A5 JP 2005509680 A JP2005509680 A JP 2005509680A JP 2005509680 A JP2005509680 A JP 2005509680A JP 2006525226 A5 JP2006525226 A5 JP 2006525226A5
- Authority
- JP
- Japan
- Prior art keywords
- amyloid
- agent
- use according
- peptide
- fibril formation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 36
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 36
- 239000003795 chemical substances by application Substances 0.000 claims 26
- 230000015572 biosynthetic process Effects 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- -1 substituted alkyl sulfonic acids Chemical class 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 230000003941 amyloidogenesis Effects 0.000 claims 6
- 210000004556 brain Anatomy 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 210000000987 immune system Anatomy 0.000 claims 5
- 239000000816 peptidomimetic Substances 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical group [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 claims 3
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000037259 Amyloid Plaque Diseases 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229940125723 sedative agent Drugs 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims 1
- 101150037123 APOE gene Proteins 0.000 claims 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 claims 1
- 208000006888 Agnosia Diseases 0.000 claims 1
- 241001047040 Agnosia Species 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 1
- 208000007415 Anhedonia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003062 Apraxia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 102000003914 Cholinesterases Human genes 0.000 claims 1
- 108090000322 Cholinesterases Proteins 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010010947 Coordination abnormal Diseases 0.000 claims 1
- 206010012239 Delusion Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010017577 Gait disturbance Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010060860 Neurological symptom Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 229940127315 Potassium Channel Openers Drugs 0.000 claims 1
- 108010050254 Presenilins Proteins 0.000 claims 1
- 206010037180 Psychiatric symptoms Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010040030 Sensory loss Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041243 Social avoidant behaviour Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 206010042458 Suicidal ideation Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000001800 adrenalinergic effect Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 1
- 230000003942 amyloidogenic effect Effects 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 229940070021 anabolic steroids Drugs 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 229940030486 androgens Drugs 0.000 claims 1
- 230000001466 anti-adreneric effect Effects 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000003257 anti-anginal effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940127088 antihypertensive drug Drugs 0.000 claims 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 239000003200 antithyroid agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003651 basophil Anatomy 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940125690 blood glucose regulator Drugs 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 230000007541 cellular toxicity Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000000064 cholinergic agonist Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 229940048961 cholinesterase Drugs 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 231100000868 delusion Toxicity 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 230000008826 genomic mutation Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000000937 inactivator Effects 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000016290 incoordination Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000006724 microglial activation Effects 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000036963 noncompetitive effect Effects 0.000 claims 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 239000011251 protective drug Substances 0.000 claims 1
- 229940001470 psychoactive drug Drugs 0.000 claims 1
- 239000004089 psychotropic agent Substances 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 125000004436 sodium atom Chemical group 0.000 claims 1
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 239000005495 thyroid hormone Substances 0.000 claims 1
- 229940036555 thyroid hormone Drugs 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43637902P | 2002-12-24 | 2002-12-24 | |
| US48221403P | 2003-06-23 | 2003-06-23 | |
| PCT/CA2003/002021 WO2004058239A1 (en) | 2002-12-24 | 2003-12-24 | Therapeutic formulations for the treatment of beta-amyloid related diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006525226A JP2006525226A (ja) | 2006-11-09 |
| JP2006525226A5 true JP2006525226A5 (https=) | 2007-02-08 |
Family
ID=32685452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005509680A Withdrawn JP2006525226A (ja) | 2002-12-24 | 2003-12-24 | β−アミロイド関連疾患の治療のための治療用製剤 |
| JP2005509679A Pending JP2006512417A (ja) | 2002-12-24 | 2003-12-24 | β−アミロイド関連疾患の治療のための治療用製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005509679A Pending JP2006512417A (ja) | 2002-12-24 | 2003-12-24 | β−アミロイド関連疾患の治療のための治療用製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060135403A1 (https=) |
| EP (2) | EP1585520A1 (https=) |
| JP (2) | JP2006525226A (https=) |
| KR (1) | KR20050101537A (https=) |
| AU (2) | AU2003292936A1 (https=) |
| BR (1) | BR0317747A (https=) |
| CA (2) | CA2511606A1 (https=) |
| EA (1) | EA012325B1 (https=) |
| IL (1) | IL169338A0 (https=) |
| MX (1) | MXPA05006940A (https=) |
| NO (1) | NO20053077L (https=) |
| NZ (1) | NZ541282A (https=) |
| WO (2) | WO2004058239A1 (https=) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| EP1628663B1 (en) * | 2003-05-15 | 2009-07-29 | Roskamp Research llc | Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| CA2528627A1 (en) * | 2003-06-23 | 2005-01-06 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| AU2011250847B2 (en) * | 2003-06-23 | 2013-06-20 | Bhi Limited Partnership | Methods and compositions for treating amyloid-related diseases |
| EP1644325A2 (en) * | 2003-06-23 | 2006-04-12 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| KR20110140139A (ko) * | 2003-08-29 | 2011-12-30 | 오노 야꾸힝 고교 가부시키가이샤 | Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
| JP4696079B2 (ja) | 2003-12-17 | 2011-06-08 | ヤンセン アルツハイマー イミュノセラピー | Ａβ免疫原性ペプチド担体結合物およびそれの製造方法 |
| CN1960781A (zh) * | 2004-04-14 | 2007-05-09 | 沃尼尔·朗伯有限责任公司 | 治疗阿尔茨海默氏病的治疗组合 |
| EP1841460A2 (en) * | 2004-06-18 | 2007-10-10 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| JP4717537B2 (ja) * | 2004-08-31 | 2011-07-06 | 株式会社 資生堂 | 皮膚外用組成物 |
| EP1828111A2 (en) * | 2004-11-12 | 2007-09-05 | Neurochem (International) Limited | Methods and fluorinated compositions for treating amyloid-related diseases |
| BRPI0519243A2 (pt) * | 2004-12-22 | 2009-01-06 | Neurochem Int Ltd | mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| US7420071B2 (en) * | 2005-05-04 | 2008-09-02 | Uchicago Argonne, Llc | Thermally stable surfactants and compositions and methods of use thereof |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| EP1959996A2 (en) | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoclonal antibody |
| KR101152557B1 (ko) | 2005-12-12 | 2012-09-07 | 에이씨 이뮨 에스.에이. | 치료 백신 |
| MX2008008213A (es) | 2005-12-22 | 2008-09-03 | Neurochem Int Ltd | Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias. |
| CA2675230A1 (en) * | 2006-01-10 | 2008-07-26 | Pipex, Inc. | Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
| MY153248A (en) | 2006-07-14 | 2015-01-29 | Ac Immune Sa | Humanized antibody against amyloid beta |
| EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| DK2089417T3 (en) * | 2006-10-12 | 2015-03-23 | Bhi Ltd Partnership | Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid |
| US8188046B2 (en) | 2006-10-16 | 2012-05-29 | University Of South Florida | Amyloid beta peptides and methods of use |
| KR101450356B1 (ko) | 2006-11-24 | 2014-10-15 | 에이씨 이뮨 에스.에이. | 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US7618944B2 (en) * | 2007-03-01 | 2009-11-17 | Intezyne Technologies, Inc. | Encapsulated amyloid-beta peptides |
| WO2008142560A2 (en) * | 2007-05-24 | 2008-11-27 | Simone Arca | Method for the production of binary clathrate hydrates of hydrogen |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| ES2529174T3 (es) | 2007-06-12 | 2015-02-17 | Ac Immune S.A. | Anticuerpos humanizados para amiloide beta |
| NZ581835A (en) | 2007-06-12 | 2012-09-28 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| EP2182978A4 (en) | 2007-07-20 | 2012-03-21 | Sanomune Inc | TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN |
| EP2044951A1 (en) | 2007-10-02 | 2009-04-08 | Merz Pharma GmbH & Co. KGaA | The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases |
| NZ584729A (en) | 2007-10-05 | 2012-12-21 | Alzheimer S Inst Of America Inc | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
| AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| BRPI0818623A2 (pt) | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal |
| WO2009059239A2 (en) * | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| EP2149380A1 (en) * | 2008-07-29 | 2010-02-03 | Medivet Pharma, S.L. | Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction. |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| WO2010042603A1 (en) * | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
| HUE055739T2 (hu) | 2009-03-18 | 2021-12-28 | Ac Immune Sa | Eljárás terápiás alkalmazásra |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| JP5051274B2 (ja) | 2009-06-04 | 2012-10-17 | 住友化学株式会社 | 加硫ゴムが有する粘弾性特性を改善させるためのｓ−（３−アミノプロピル）チオ硫酸および／またはその金属塩の使用 |
| EP2311823A1 (en) | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| AU2011239966B2 (en) | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| EP2377860A1 (en) | 2010-04-16 | 2011-10-19 | AC Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| JP6027011B2 (ja) | 2010-10-26 | 2016-11-16 | エーシー イミューン ソシエテ アノニム | 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物 |
| US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
| EA201391017A1 (ru) | 2011-01-10 | 2014-04-30 | Зинфандел Фармасьютикалз, Инк. | Способы и готовые лекарственные формы для лечения болезни альцгеймера |
| WO2013009799A1 (en) * | 2011-07-11 | 2013-01-17 | Beth Israel Deaconess Medical Center, Inc. | Vitamin d receptor agonists and uses thereof |
| CA2811188C (en) | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| KR101981351B1 (ko) | 2011-10-07 | 2019-09-02 | 에이씨 이뮨 에스.에이. | 타우를 인식하는 포스포특이적 항체 |
| RU2644242C2 (ru) | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| US20130323222A1 (en) | 2012-06-04 | 2013-12-05 | Matthew Charles | Human tissue kallikrein 1 glycosylation isoforms |
| CA3132310C (en) * | 2012-08-07 | 2024-01-09 | Children's Medical Center Corporation | Potassium channel openers for treating neurodegenerative diseases |
| PL2931276T3 (pl) * | 2012-12-13 | 2018-06-29 | H. Lundbeck A/S | Kompozycje zawierające wortioksetynę i donepezil |
| US9200068B2 (en) * | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
| WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
| WO2015110263A1 (en) | 2014-01-21 | 2015-07-30 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins |
| US10314911B2 (en) * | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
| KR102298676B1 (ko) * | 2014-05-09 | 2021-09-07 | 테크니메데 소시에다데 테크니코-메디시날 에스.에이. | 의약으로서 사용되기 위한 (s)-펄린돌 및 약학적으로 허용 가능한 그의 염 |
| TN2016000497A1 (en) * | 2014-05-09 | 2018-04-04 | Tecnimede Sociedade Tecnico Medicinal S | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine |
| CN107428820B (zh) | 2014-11-19 | 2022-03-22 | 阿克松神经系统科学公司 | 在阿尔茨海默氏病中的人源化tau抗体 |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| MX380290B (es) | 2015-08-10 | 2025-03-12 | Alzheon Inc | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. |
| EP3374381A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF |
| AU2016353553B2 (en) | 2015-11-09 | 2022-01-20 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
| KR102776187B1 (ko) | 2015-11-09 | 2025-03-07 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체 |
| ITUA20161679A1 (it) | 2016-03-15 | 2017-09-15 | Neuraxpharm Italy S P A | Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi |
| CN109476729A (zh) | 2016-07-18 | 2019-03-15 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
| WO2018038973A1 (en) * | 2016-08-20 | 2018-03-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Neuroprotective beta amyloid core peptides and peptidomimetic derivatives |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| MX2019006330A (es) | 2016-12-07 | 2019-09-26 | Genentech Inc | Anticuerpos anti-tau y metodos de uso. |
| UA128383C2 (uk) | 2016-12-07 | 2024-07-03 | Дженентек, Інк. | Антитіло до тау-білка та спосіб його застосування |
| AU2018230478B2 (en) | 2017-03-09 | 2025-01-23 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
| EP3601337A1 (en) | 2017-03-28 | 2020-02-05 | Genentech, Inc. | Methods of treating neurodegenerative diseases |
| AU2018260628A1 (en) * | 2017-04-25 | 2019-12-12 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
| KR101917128B1 (ko) | 2017-04-28 | 2018-11-09 | 강원대학교산학협력단 | 산양삼 추출물을 포함하는 알츠하이머병의 예방 또는 치료용 약학 조성물 |
| WO2019018445A1 (en) * | 2017-07-17 | 2019-01-24 | Maxwell Biosciences, Inc. | POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US20200330592A1 (en) * | 2017-10-09 | 2020-10-22 | Keith Black | Compositions and methods of treating alzheimer's and other amyloid related diseases |
| CN111787942B (zh) | 2017-10-25 | 2024-03-29 | 杨森制药公司 | 磷酸化Tau肽的组合物及其用途 |
| PE20211090A1 (es) | 2018-01-05 | 2021-06-14 | Ac Immune Sa | Derivados de 1,3,4,5-tetrahidro-2h-pirido[4,3-b]indol para el tratamiento, alivio o prevencion de trastornos asociados con los agregados de tau |
| SG11202008098TA (en) | 2018-03-28 | 2020-10-29 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
| CN112351984B (zh) | 2018-06-04 | 2024-01-02 | Ac免疫有限公司 | 用于治疗、缓解或预防与Tau聚集物相关病症的四氢苯并呋喃并[2.3-c]吡啶和β-咔啉化合物 |
| CN112313230B (zh) | 2018-06-04 | 2024-03-15 | Ac免疫有限公司 | 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物 |
| KR20200086198A (ko) | 2019-01-08 | 2020-07-16 | 주식회사 솔고 바이오메디칼 | 수소 흡장 금속을 포함하는 치매 예방 또는 치료용 조성물 |
| WO2020150423A1 (en) * | 2019-01-16 | 2020-07-23 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| MY206596A (en) | 2019-02-08 | 2024-12-25 | Janssen Pharmaceuticals Inc | Method of safe administration of phosphorylated tau peptide vaccine |
| JP7232931B2 (ja) | 2019-03-01 | 2023-03-03 | エイシー イミューン ソシエテ アノニム | タウ凝集体に関連する障害の治療、緩和、または予防のための新規化合物 |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| WO2021067850A2 (en) * | 2019-10-02 | 2021-04-08 | Washington University | METHODS OF DETECTING circRNA |
| ES2821599A1 (es) | 2019-10-24 | 2021-04-26 | Univ Del Pais Vasco / Euskal Herriko Unibertsitatea | Compuestos y metodos para el tratamiento de la enfermedad de alzheimer |
| CN112939823A (zh) * | 2019-12-10 | 2021-06-11 | 中国石油天然气股份有限公司 | 泥页岩抑制剂制备方法及抑制剂的应用 |
| KR20210133603A (ko) | 2020-04-29 | 2021-11-08 | 정지영 | 굼벵이를 포함하는 치매 예방 또는 치료용 조성물 |
| WO2021231566A1 (en) * | 2020-05-12 | 2021-11-18 | Massachusetts Institute Of Technology | The use of choline supplementation as therapy for apoe4-related disorders |
| AR123730A1 (es) | 2020-10-15 | 2023-01-04 | Ac Immune Sa | Compuestos novedosos |
| JP7682515B2 (ja) * | 2020-12-11 | 2025-05-26 | 国立研究開発法人国立長寿医療研究センター | 認知症の危険性判定システムおよび認知症の危険性判定用プログラム |
| KR102598904B1 (ko) * | 2022-12-16 | 2023-11-06 | 닥터노아바이오텍 주식회사 | 콜린에스터라제 억제제의 부작용 예방 또는 치료용 조성물 |
| JP2024534151A (ja) | 2021-08-27 | 2024-09-18 | ジェネンテック， インコーポレイテッド | タウ病態の治療方法 |
| CN115624555A (zh) * | 2022-02-24 | 2023-01-20 | 中国药科大学 | 猪去氧胆酸在制备抗抑郁药物中的应用 |
| CN118871989A (zh) | 2022-03-14 | 2024-10-29 | 基因泰克公司 | 基于语音分析来预测神经退行性疾病 |
| KR20230147988A (ko) * | 2022-04-15 | 2023-10-24 | 아주대학교산학협력단 | Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물 |
| JP2025525371A (ja) | 2022-06-21 | 2025-08-05 | ジェネンテック， インコーポレイテッド | 音声分析に基づくアルツハイマー病（ａｄ）の長期的進行の検出 |
| WO2026037826A1 (en) | 2024-08-12 | 2026-02-19 | Ac Immune Sa | 2,4-dihydropyrazolo[3',4':4,5]pyrano[2,3-b]pyridine compounds |
| CN119570766B (zh) * | 2025-02-08 | 2025-05-16 | 上海锴泰生物科技有限公司 | 一种胶原蛋白酶突变体、基因片段、重组质粒、重组表达体系、胶原蛋白肽，及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| WO1994022437A2 (en) * | 1993-03-29 | 1994-10-13 | Queen's University At Kingston | Method for treating amyloidosis |
| WO1997021728A1 (en) * | 1995-12-12 | 1997-06-19 | Karolinska Innovations Ab | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
| JPH10259126A (ja) * | 1997-01-17 | 1998-09-29 | Takeda Chem Ind Ltd | アルツハイマー病治療・予防剤 |
| CA2320224C (en) * | 1998-02-11 | 2008-08-12 | Neurochem, Inc. | Method for modulating macrophage activation |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| WO1999059571A1 (en) * | 1998-05-15 | 1999-11-25 | Neurochem, Inc. | Use of amyloid inhibitors for modulating neuronal cell death |
| ATE366259T1 (de) * | 1999-03-04 | 2007-07-15 | Praecis Pharm Inc | Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren |
| IL146143A0 (en) * | 1999-04-28 | 2002-07-25 | Univ Kingston | Compositions and methods for treating amyloidosis |
| ATE384077T1 (de) * | 1999-05-05 | 2008-02-15 | Neurochem Int Ltd | Stereoselektive antifibrillogene peptide |
| US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| EP1251837A2 (en) * | 1999-12-23 | 2002-10-30 | Neurochem, Inc. | Compounds and methods for modulating cerebral amyloid angiopathy |
| US20020151591A1 (en) * | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| EP1538163A3 (en) * | 2000-11-01 | 2005-06-15 | Insight Biotechnology Limited | Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20050038000A1 (en) * | 2003-06-23 | 2005-02-17 | Xianqi Kong | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases |
| US7253306B2 (en) * | 2003-06-23 | 2007-08-07 | Neurochem (International) Limited | Pharmaceutical drug candidates and methods for preparation thereof |
-
2003
- 2003-12-24 AU AU2003292936A patent/AU2003292936A1/en not_active Abandoned
- 2003-12-24 CA CA002511606A patent/CA2511606A1/en not_active Abandoned
- 2003-12-24 WO PCT/CA2003/002021 patent/WO2004058239A1/en not_active Ceased
- 2003-12-24 US US10/540,763 patent/US20060135403A1/en not_active Abandoned
- 2003-12-24 JP JP2005509680A patent/JP2006525226A/ja not_active Withdrawn
- 2003-12-24 BR BR0317747-5A patent/BR0317747A/pt not_active IP Right Cessation
- 2003-12-24 KR KR1020057012003A patent/KR20050101537A/ko not_active Ceased
- 2003-12-24 WO PCT/CA2003/002011 patent/WO2004058258A1/en not_active Ceased
- 2003-12-24 NZ NZ541282A patent/NZ541282A/en unknown
- 2003-12-24 CA CA002511599A patent/CA2511599A1/en not_active Abandoned
- 2003-12-24 EP EP03767368A patent/EP1585520A1/en not_active Withdrawn
- 2003-12-24 JP JP2005509679A patent/JP2006512417A/ja active Pending
- 2003-12-24 MX MXPA05006940A patent/MXPA05006940A/es active IP Right Grant
- 2003-12-24 EP EP03788737A patent/EP1581203A1/en not_active Withdrawn
- 2003-12-24 EA EA200501023A patent/EA012325B1/ru not_active IP Right Cessation
- 2003-12-24 AU AU2003291910A patent/AU2003291910B2/en not_active Ceased
-
2005
- 2005-06-22 IL IL169338A patent/IL169338A0/en unknown
- 2005-06-23 NO NO20053077A patent/NO20053077L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006525226A5 (https=) | ||
| US12409176B2 (en) | Methods of treating acute depression | |
| ES2378776T3 (es) | Derivado de ácido aminocarboxílico y uso medicinal del mismo | |
| US5260322A (en) | Angiotension II antagonists in the treatment of hyperuricemia | |
| KR101636395B1 (ko) | 허혈 및 허혈 재관류 손상을 치료하기 위한 조성물 및 방법 | |
| JP2021519271A (ja) | 有機化合物 | |
| JP2632754B2 (ja) | 脳内グルタミン酸遊離抑制剤 | |
| TW201811798A (zh) | sGC 刺激劑 | |
| KR20170003527A (ko) | 경구 투여용 펜토산 폴리설페이트 염의 조성물 | |
| JP2010531879A (ja) | 水素化ピリド［４，３−ｂ］インドールに基づく抗不安作用を示す薬物、その薬理学的な化合物および適用方法 | |
| JP2006512417A5 (https=) | ||
| JPH0621070B2 (ja) | ジアゼピン含有医薬組成物 | |
| FR2617713A1 (fr) | Nouvelle utilisation des antagonistes de 5ht-3 | |
| JP2010511701A (ja) | 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた、発作を含む脳循環の急性および慢性疾患の治療のための手段、それに基づいた薬理学的手段、およびその使用のための方法 | |
| WO2020186010A1 (en) | Cannabinoid acid ester compositions and uses thereof | |
| JP2012512165A (ja) | 四環系ピラジノインドールを用いた多発性硬化症の治療方法 | |
| KR20050057673A (ko) | Ｊｎｋ 억제제를 이용한 통증의 치료 | |
| JP2012505257A (ja) | 多発性硬化症治療のための組成物および方法 | |
| JPWO2020050253A1 (ja) | 糖尿病性末梢神経障害のための医薬 | |
| Sorbera et al. | Pagoclone | |
| EP4525828A1 (en) | Treatments with nirogacestat | |
| JP2012502915A (ja) | てんかんを治療する組成物及び方法 | |
| CN101189004A (zh) | 疼痛的治疗 | |
| WO2000066595A1 (en) | Heterocyclic carboxylic acid derivatives | |
| JP2007502297A (ja) | コリンエステラーゼ阻害剤を用いる睡眠障害の処置 |